We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Syncona Limited (SYNC) Ordinary NPV

Sell:99.50p Buy:99.80p 0 Change: No change
FTSE 250:0.52%
Market closed |  Prices as at close on 22 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:99.50p
Buy:99.80p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:99.50p
Buy:99.80p
Change: No change
Market closed |  Prices as at close on 22 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

News, reports & tips

  • Syncona launches Slingshot platform with £12.5m investment

    14 November 2024 11:34

    (Sharecast News) - Syncona announced the launch of Slingshot Therapeutics, a new portfolio company and accelerator dedicated to developing early-stage life science programs sourced from academia, on Thursday.

  • Syncona's Autolus gets FDA approval for leukaemia treatment

    11 November 2024 07:17

    (Sharecast News) - Life science investor Syncona announced on Monday that its portfolio company Autolus Therapeutics has received US Food and Drug Administration (FDA) approval for Aucatzyl (obe-cel), a CAR...

  • Syncona's Purespring raises £80m in new financing

    9 October 2024 07:21

    (Sharecast News) - Life science investor Syncona said its portfolio company Purespring Therapeutics, which focuses on gene therapies for kidney diseases, had raised £80m in an oversubscribed financing.

  • Syncona commits £63.5m to Resolution Therapies

    3 October 2024 12:14

    (Sharecast News) - Syncona announced on Thursday that it has committed £63.5m in series B financing to Resolution Therapeutics, a portfolio company focused on macrophage therapy for inflammatory and...

  • Syncona confident in portfolio despite fall in NAV

    13 August 2024 11:57

    (Sharecast News) - Life science investor Syncona reported significant developments in its portfolio during its first quarter on Tuesday, despite a slight decline in net assets.

  • Syncona adds two oncology investments to portfolio

    20 June 2024 12:11

    (Sharecast News) - Life science investor Syncona announced the addition of two new oncology companies to its portfolio on Thursday.

  • Syncona reports positive findings from investee Freeline

    9 May 2024 11:19

    (Sharecast News) - Life science investor Syncona reported positive findings from its portfolio company Freeline Therapeutics on Thursday, after a phase one and two study of its gene therapy candidate for...

  • Syncona NAV grows in Q3

    8 February 2024 09:04

    (Sharecast News) - Life sciences investor Syncona said on Thursday that its net asset value had grown in the three months ended 31 December, driven by a prioritisation of capital allocation across its...

  • Syncona net asset value falls, co-founder steps down

    16 November 2023 08:44

    (Sharecast News) - Life science specialist Syncona reported a net asset value of £1.2bn at the end of its first half on Thursday, down from £1.25bn on 31 March, with a net asset value return of -4.2%...

  • Syncona shares slump as Novartis ends eye treatment development

    11 September 2023 15:42

    (Sharecast News) - Syncona shares fell as the UK healthcare investment firm said Novartis had stopped the development of experimental eye treatment, GT005, resulting in milestone payments write-off of...

  • Syncona reports slight dip in net assets

    10 August 2023 08:34

    (Sharecast News) - Healthcare investor Syncona reported a slight dip in net assets in its quarterly update on Thursday, to £1.24bn, down from £1.26bn at the end of March.

  • Syncona annual NAV falls in tough macro conditions

    15 June 2023 07:39

    (Sharecast News) - Health investor Syncona reported a fall in annual net asset value, driven by falls in its listed holdings and the partial write-down of neurological gene therapy company SwanBio, partially...

Company announcements Announcements


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.

© Digital Look Ltd 1998-2024. All rights reserved.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.